Compare HGLB & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HGLB | GBIO |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.7M | 35.4M |
| IPO Year | N/A | 2020 |
| Metric | HGLB | GBIO |
|---|---|---|
| Price | $9.20 | $5.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | ★ 91.8K | 40.1K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 13.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,270,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.42 | $3.00 |
| 52 Week High | $9.45 | $13.00 |
| Indicator | HGLB | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 51.71 |
| Support Level | $9.38 | $5.22 |
| Resistance Level | $9.74 | $5.64 |
| Average True Range (ATR) | 0.30 | 0.25 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 9.00 | 67.19 |
Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.